GSK's discount unwarranted, especially with latest Zantac win, says brokerProactive Investors • 08/16/24
GSK: Robust Financials, Strong Portfolio And Sector Rotation To Defensives Make It A BuySeeking Alpha • 08/06/24
GSK sees £1.2bn wiped from its value as investors grumble about vaccine missProactive Investors • 07/31/24
GSK Beats Second-Quarter Views, Raises Outlook; But Shares Fall On Shingrix MissInvestors Business Daily • 07/31/24